×

Once registered, you can:

  • - Read additional free articles each month
  • - Comment on articles and featured creative work
  • - Get our curated newsletters delivered to your inbox

By registering you agree to our privacy policy, terms & conditions and to receive occasional emails from Ad Age. You may unsubscribe at any time.

Are you a print subscriber? Activate your account.

BBDO SELECTED FOR $10 MILLION DRUG ACCOUNT

Will Handle Advertising for Dey Epinephrine Injector System

By Published on .

NEW YORK (AdAge.com) -- Dey L.P. is poised to select Omnicom Group's BBDO Worldwide, New York, to handle a $10 million account for EpiPen after a review, according to executives close to the situation.

EpiPen is an automatic injector that allows people to self-administer epinephrine in case of severe allergic reactions to food, bee stings or latex, for instance.

BBDO referred calls to the client; Dey declined to comment. The other agencies could not immediately be reached for comment.

BBDO beat out incumbent Gillespie Advertising, Princeton, N.J.; Interpublic Group of Cos.' McCann-Erickson Worldwide, New York; and independent Wishbone, New York.

Dey is an affiliate of EMD Pharmaceuticals in Durham, N.C., a division of pharmaceutical giant Merck.

Most Popular